Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00888329 · ClinicalTrials.gov registry record · Phase 4
Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy
A Phase 4 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 256
- Enrollment target
NCT00888329: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT00888329 is a Phase 4 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 256 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00888329, a Phase 4 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 256 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether 40 mg aprepitant administered before surgery is effective for preventing vomiting in the first 24 hours after surgery in women undergoing elective hysterectomy.
Interventions
- DRUG Placebo
- DRUG Aprepitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00888329
The ClinicalTrials.gov registry entry for NCT00888329 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00888329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00888329 about?
NCT00888329 is a clinical study titled "Aprepitant for Prevention of Postoperative Nausea and Vomiting in Elective Hysterectomy". The purpose of the study is to determine whether 40 mg aprepitant administered before surgery is effective for preventing vomiting in the first 24 hours after surgery in women undergoing elective hysterectomy.
What is the current status of trial NCT00888329?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 256 participants. The study started on 2007-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00888329?
The interventions under investigation include: Placebo (DRUG), Aprepitant (DRUG).
Who is sponsoring clinical trial NCT00888329?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.